Zevra Therapeutics, Inc. (ZVRA) Company Total Revenue

Corporate emblem and logo of Zevra Therapeutics Inc (ZVRA)

The promising business of Zevra Therapeutics (ZVRA) relies on the success of Miplyffa and royalties from ADHD treatments. The company's sales volume dynamics demonstrate a current trend, where 0.15 describes the current status of the metric. The model operates through the full outsourcing of drug production to third-party vendors. Strong pricing power is ensured by inelastic demand for unique medications used to treat rare genetic pathologies.

ZVRA - Zevra Therapeutics, Inc. Company Revenue over the range 04/28/2023 - 11/17/2026

Analytical breakdowns for zevra.com (ZVRA)

- share price and expert price forecast:
- market capitalization details:
General company analysis:Zevra Therapeutics (ZVRA)
Mass-produced product of Zevra Therapeutics

Sales reflect the daily cash inflow from product realization compared to historical demand. An investor analyzes the Zevra Therapeutics (ZVRA) sales revenue chart on GURU.Markets to assess the business's resilience to inflationary risks. This metric's trend captures actual consumer activity. For Zevra Therapeutics (ZVRA), this indicator confirms the effectiveness of its proprietary development platform. Pricing power in the CNS orphan disease niche ensures stable revenue growth.